BIOTECH CATALYST AI SCANNER — July WK5

The tape going into August is a study in exhaustion. Look down this week's featured list and the striking thing isn't the catalysts — it's how many of these names are trading like the market has already given up on them. Beam sits at an RSI of 6. Ionis at 10. Moderna at 16. Zymeworks at 16. When a cohort this large is this deeply oversold heading into hard catalysts, you're no longer trading the science in a vacuum — you're trading it against positioning that has already emptied out. Some of that is deserved. Some of it is the setup.

August is also a regulatory month. Four of this week's names carry firm PDUFA or topline dates in the next four weeks — Moderna's flu vaccine (Aug 5), Zymeworks' gastric cancer decision (Aug 25), plus pivotal readouts from Silence and Tenax. The rest are "mid-2026" estimates that resolve to August by the scanner's dating. Read the date granularity accordingly: an "Aug 2026 (Est.)" is a company-guided window, not a confirmed calendar date.

One entry needs a warning label up front. Ionis appears at #10 around a trial that has already failed — eplontersen missed its primary endpoint in ATTR-CM on July 9. It's on the list because the full dataset gets presented at ESC in late August, but this is a post-mortem and a subgroup-salvage story, not a pending binary. Treat it as such.

What We're Tracking:

Trading Below Cash (Negative EV): ACET
Cash Pressure: NTHI (~$0.9M cash), RARE, CHRS
Initial / First-in-Human Data: SLN, AVBP, LGVN, TENX, EYPT, SION, AVIR
Deeply Oversold (RSI < 20): BEAM, IONS, MRNA, ZYME, STRO
Multi-Catalyst (90 days): EYPT, SION, NTHI

FEATURED

#1. SLN — Silence Therapeutics Plc

THE CATALYST
Event: Divesiran (SLN124) — Phase 2 topline data in polycythemia vera
Date: Aug 2026 (Est.)
FDA Status: FTD, ODD
BSI: 7.9/10

Silence is the rare small-cap heading into a pivotal readout with momentum on its side rather than against it — the stock is up on rising volume while most of this week's list bleeds out. The company builds siRNA (small interfering RNA — molecules that switch off a specific gene) therapeutics, and divesiran is its lead wholly-owned asset after years of platform partnerships. Cash is flagged as unverified in our feed but reconciles to roughly $70M and a runway into 2028.

📈 The Setup: Polycythemia vera (a blood cancer that overproduces red cells) is managed today by physically draining blood — therapeutic phlebotomy — plus agents like ropeginterferon (Besremi). Divesiran attacks the problem upstream: it silences TMPRSS6, which raises hepcidin, the hormone that restricts iron availability for red-cell production. Starve the iron, throttle the overproduction. The SANRECO Phase 2 enrolled 48 phlebotomy-dependent patients on a convenient every-6-week or every-12-week dosing schedule, with the primary endpoint measuring how many maintain hematocrit below 45% without phlebotomy. Earlier Phase 1 follow-up already showed phlebotomies essentially eliminated and the effect persisting after dosing stopped — the data point underpinning the best-in-class convenience thesis. This is a genuine topline efficacy readout, not an interim peek.

✅ The Edge: The most direct rival, Takeda/Protagonist's rusfertide, also works the hepcidin axis but requires weekly injections; divesiran's Q12W arm is testing a dosing interval no competitor can match. FDA has already accepted phlebotomy reduction as a registrational endpoint here.
⚠️ The Risk: A 48-patient trial is small — any imbalance in background cytoreductive therapy between arms could blur the placebo separation the whole thesis rests on.

#2. AVBP — ArriVent BioPharma Inc.

THE CATALYST
Event: Furmonertinib — Phase 3 topline data in 1L EGFR exon 20 insertion NSCLC
Date: Aug 2026 (Est.)
FDA Status: BTD
BSI: 7.34/10

ArriVent's whole value case rests on a single Phase 3, and the market has been fading the name into it — shares are down double digits over the past month despite a healthy balance sheet. The company licensed furmonertinib from Shanghai Allist and has built its pipeline around this lead oral EGFR inhibitor. Cash of roughly $326M funds operations into late 2027, so the FURVENT readout is not a financing-gun-to-the-head situation.

📈 The Setup: EGFR exon 20 insertion NSCLC (a subset of lung cancer driven by a specific mutation that most EGFR pills can't reach) has been dominated by J&J's amivantamab (Rybrevant), an infused antibody with a difficult tolerability profile. Furmonertinib is an oral, brain-penetrant EGFR inhibitor going head-to-head in the first-line setting — the FURVENT Phase 3 pits it against chemotherapy with progression-free survival by blinded independent review as the primary endpoint. Its Breakthrough Therapy Designation was granted specifically on Phase 1b durability and central-nervous-system activity, an edge most oral competitors haven't matched. An oral drug that controls brain metastases and spares patients infusion chairs is a real commercial wedge — if the Phase 3 confirms what the early data implied. This is the pivotal, registration-enabling readout.

✅ The Edge: CNS penetration plus oral dosing differentiates it from Rybrevant's infusion burden, and the BTD signals FDA sees the same gap. Few oral exon 20 competitors have shown comparable durability.
⚠️ The Risk: FDA has scrutinized surrogate endpoints in prior exon 20 programs — if the agency demands mature overall-survival data rather than accepting PFS, approval slips well beyond the current runway.

#3. LGVN — Longeveron Inc.

THE CATALYST
Event: Laromestrocel (lomecel-B) — Phase 2b topline data in hypoplastic left heart syndrome
Date: Aug 2026 (Est.)
FDA Status: FTD, ODD
BSI: 7.23/10

A $19M market cap with a BLA already in its stated plans tells you the market is pricing in failure — or at least deep skepticism. Longeveron raised a $30M private placement in March (Coastlands Capital led, with Janus Henderson participating), which is what keeps the lights on through the readout, though runway still only reaches Q4 2026. This is a cell-therapy company betting everything on one rare-pediatric indication.

📈 The Setup: Hypoplastic left heart syndrome (a birth defect where the left side of the heart is critically underdeveloped) is treated with a brutal sequence of three staged open-heart surgeries, and there is no drug that improves the outcome. Laromestrocel is an allogeneic mesenchymal stem-cell therapy (donor-derived cells given off-the-shelf) delivered during surgery to strengthen the underbuilt right ventricle that has to do the work of two. The ELPIS II Phase 2b reads out this quarter, and the setup is unusually de-risked for a name this small: the independent data monitoring committee reviewed unblinded data in May and endorsed continuation, and management says its endpoints align with FDA Type C feedback pointing toward a potential BLA. No competitor is developing a pharmacological alternative — the comparator is surgery alone.

✅ The Edge: First-mover in an indication with zero drug competition and an orphan population, backed by a DMC that has already seen the data and waved the trial through — a signal a blinded outside investor cannot get on their own.
⚠️ The Risk: Micro-cap biology risk is real: mesenchymal stem-cell therapies have a long history of encouraging mid-stage signals that evaporate in confirmatory trials, and a composite endpoint in 30-odd patients is fragile.

#4. PYXS — Pyxis Oncology Inc.

THE CATALYST
Event: Micvotabart pelidotin (MICVO) — Phase 1 interim data in solid tumors
Date: Aug 2026 (Est.)
BSI: 6.83/10

Pyxis just bought itself breathing room — a June 30 private placement (~$50M upfront, led by BVF Partners) reset the runway from near-zero to Q2 2027, defusing what had been an acute financing squeeze heading into the data. The company is a focused antibody-drug conjugate developer, and micvotabart pelidotin (MICVO) is its lead program. That financing timing matters: the setup is a pressure cooker, but the pressure is now on the data, not the balance sheet.

📈 The Setup: Most antibody-drug conjugates — antibodies wired to a chemotherapy payload — target proteins on the tumor cell surface, and they stumble when those targets vary from cell to cell. MICVO instead aims at EDB+ fibronectin, a protein in the tumor's supporting scaffold (stroma) that is largely absent from healthy adult tissue, which in principle lets it deliver payload across tumors with messy, heterogeneous surface markers. The most striking prior data came in head and neck cancer (HNSCC): a 46% confirmed response rate as monotherapy and 71% in combination with Keytruda (pembrolizumab) in earlier-line patients. The upcoming update expands that Phase 1 dataset. Read it for durability and consistency, not headline response rate — the bar an early cut sets is easy to miss on maturation.

✅ The Edge: A stromal target that sidesteps antigen heterogeneity is a genuinely differentiated ADC approach, and the combination response rate with pembrolizumab stands out against entrenched checkpoint-inhibitor regimens.
⚠️ The Risk: This is a Phase 1 expansion, not a pivotal trial — the numbers can soften as more patients and longer follow-up come in, and a crowded 2L+ head-and-neck field with emerging EGFR bispecifics limits how much any single-arm signal is worth.

#5. MRNA — Moderna Inc.

THE CATALYST
Event: mRNA-1010 — PDUFA regulatory decision in seasonal influenza (adults 50+)
Date: Aug 05, 2026
BSI: 6.76/10

This is Moderna at maximum pessimism — RSI 16, down 17% on the month, a $22B company trading like the flu franchise is worthless. The near-term question is narrow and binary: does the FDA approve mRNA-1010 by the August 5 PDUFA date? An advisory committee already voted 9-0 in favor of the benefit-risk profile, which followed an earlier refuse-to-file — the revised path apparently resolved the comparator concerns that stalled the original filing.

📈 The Setup: Standalone seasonal flu vaccines are a mature, low-growth market owned by high-dose inactivated shots — Sanofi's Efluelda/Fluzone HD and CSL's Fluad lead the 50+ segment on the strength of established recommendations and reimbursement. Moderna's pitch is manufacturing speed: an mRNA platform can update strain composition faster than egg- or cell-based production, which matters in seasons where the circulating strain drifts from the vaccine. The unanimous AdCom vote is the key tell — it points to a standard-approval path in the 50-64 group and an accelerated path in the 65+ group with a post-marketing commitment. An approval doesn't transform the story on its own; its real value is as the first commercial validation of Moderna's non-COVID respiratory pipeline, with combination flu/COVID shots behind it.

✅ The Edge: Faster strain-matching than incumbent egg-based platforms is a concrete manufacturing advantage, and a 9-0 advisory vote is about as clean a regulatory signal as this category offers going into a PDUFA.
⚠️ The Risk: Even with approval, Sanofi and GSK own the pharmacy shelf and the guideline recommendations in the 50+ segment — clearing FDA is not the same as taking share, and the label could be restricted to the narrower 65+ accelerated indication.

#6. TENX — Tenax Therapeutics Inc.

THE CATALYST
Event: TNX-103 (oral levosimendan) — Phase 3 topline data in PH-HFpEF
Date: Aug 29, 2026
BSI: 6.54/10

A 27M-share float grinding higher on rising volume into a confirmed Phase 3 readout — Tenax is the kind of low-float name that moves violently in either direction on data day. The catalyst timing is unusually firm for a small-cap: management has confirmed the August topline and a late-breaking slot at the European Society of Cardiology Congress in a recent 8-K. Cash is flagged unverified in our feed but reconciles to roughly $119M and a runway into 2028, so this readout isn't a survival event.

📈 The Setup: Pulmonary hypertension with heart failure and preserved ejection fraction — PH-HFpEF, a stiff-heart condition where pressure backs up into the lungs — has no approved drug and a graveyard of failed trials behind it. TNX-103 is an oral formulation of levosimendan, a calcium-sensitizer that helps the heart contract more efficiently and relaxes blood vessels; it has decades of use as an intravenous hospital drug, which lowers the novel-molecule risk even as the oral form and indication are new. The LEVEL Phase 3 has completed enrollment, with the six-minute walk distance as its registrational endpoint. The bull case is a well-understood mechanism finally tested in a population no one has cracked; the honest read is that six-minute walk as a standalone approval endpoint in this indication has no prior precedent.

✅ The Edge: Levosimendan's long IV track record de-risks the pharmacology in a way first-in-class PH-HFpEF entrants can't claim, and there is no approved competitor to displace — a clean first-mover lane if the data land.
⚠️ The Risk: The FDA has never reviewed a levosimendan NDA in this indication, and it has not committed to six-minute walk distance as sufficient for approval on its own — a positive trial could still face an endpoint fight.

#7. BEAM — Beam Therapeutics Inc.

THE CATALYST
Event: BEAM-302 — Phase 1/2 data in severe alpha-1 antitrypsin deficiency
Date: Sep 08, 2026
FDA Status: RMAT
BSI: 6.46/10

An RSI of 6 is the lowest reading on this entire list — Beam is about as washed-out as a $2.6B company gets, down 28% on the month into a data event. The balance sheet is the opposite of the chart: a non-dilutive Sixth Street facility plus proceeds from the Orbital sale push runway to mid-2029, so this is a cash-rich company whose stock has been left for dead. That gap between fundamentals and sentiment is the setup.

📈 The Setup: Alpha-1 antitrypsin deficiency (AATD — an inherited disorder where a misfolded protein damages both lung and liver) is managed today by weekly infusions of donor-derived protein (augmentation therapy) that address the lung but do nothing for the liver. BEAM-302 uses base editing — a precise gene-editing technique that rewrites a single DNA letter without cutting the strand — to correct the underlying mutation at the source. The Phase 1/2 update at the European Respiratory Society meeting in September builds on an initial 29-patient dataset where a single 60mg dose produced durable correction, with roughly 94% of circulating protein in the healthy form and a functional response under infection stress. The RMAT designation reflects how differentiated a one-time fix is versus lifelong infusions. This is still early-cohort data, not a pivotal readout — read it for durability and dose consistency.

✅ The Edge: A single-dose editor that addresses both the lung and the liver attacks a limitation augmentation therapy structurally cannot — and the closest competitor, Wave's RNA-editing WVE-006, delivers protein without permanently correcting the gene.
⚠️ The Risk: Base editing carries real regulatory weight — prior gene-therapy precedents show that off-target or manufacturing concerns can trigger complete response letters even after a biomarker endpoint is met, and a 29-patient base is thin.

#8. ZYME — Zymeworks Inc.

THE CATALYST
Event: Ziihera (zanidatamab-hrii) — PDUFA regulatory decision in 1L HER2+ gastroesophageal adenocarcinoma
Date: Aug 25, 2026
BSI: 6.37/10

Positive Phase 3 in hand, published in the New England Journal, PDUFA on the calendar — and the stock is at an RSI of 16 on almost no volume. Zymeworks has been diversifying away from single-asset risk: a March royalty-backed note from Royalty Pharma and a June all-cash acquisition of Theravance Biopharma broaden the base beyond this one decision. Partner Jazz Pharmaceuticals runs the sBLA and commercialization for zanidatamab.

📈 The Setup: First-line HER2-positive gastroesophageal adenocarcinoma (GEA — cancer of the stomach and the junction where the esophagus meets it) has been anchored for years on trastuzumab plus chemotherapy and a checkpoint inhibitor. Zanidatamab is a bispecific antibody that binds two separate spots on the HER2 protein at once, driving stronger receptor clustering and internalization than standard single-target trastuzumab. HERIZON-GEA-01 is the first Phase 3 to beat trastuzumab-plus-chemo on both progression-free and overall survival in this setting — median PFS of 12.4 versus 8.1 months, with overall survival reaching 26.4 months in the arm adding tislelizumab. The August 25 PDUFA is a regulatory decision on a trial that already succeeded, so the binary here is approval mechanics and label, not efficacy.

✅ The Edge: A dual-epitope HER2 bispecific with a positive head-to-head against the standard of care is a concrete mechanistic and clinical advantage, and NEJM publication plus Priority Review signal FDA and the field take the data seriously.
⚠️ The Risk: The HER2 space is crowded and price-competitive — trastuzumab biosimilars and physician habit create switching costs, and the FDA could narrow the label to the IHC 3+ subset, capping the addressable population.

#9. EYPT — EyePoint Inc.

THE CATALYST
Event: DURAVYU (EYP-1901) — pivotal topline data in wet age-related macular degeneration
Date: Aug 2026 (Est.)
Additional catalysts: 1 more within 90 days
BSI: 6.21/10

Two pivotal wet AMD readouts sit inside this window, and EyePoint has enough cash into late 2027 to see both through without a financing overhang. The company's entire near-term identity rests on DURAVYU, a sustained-delivery eye implant, and the LUGANO and LUCIA pivotal trials read out back-to-back. (Note: this week's technical snapshot for EYPT — RSI exactly 50, momentum exactly 0.0% — reads like placeholder values; treat the technicals here with caution.)

📈 The Setup: Wet age-related macular degeneration (a leading cause of vision loss where abnormal vessels leak under the retina) is controlled by anti-VEGF injections into the eye — Regeneron's Eylea/Eylea HD and Roche's Vabysmo (faricimab) — that many patients need every one to two months, a real adherence burden. DURAVYU is a bioerodible insert (Durasert E) that elutes a tyrosine-kinase inhibitor to suppress that vessel growth over an extended interval, targeting redosing as infrequently as every six months. LUGANO and LUCIA are testing that two-year, every-six-month regimen in both treatment-naïve and previously treated patients — the two pivotal trials that decide the program. The whole thesis is durability: can it hold vision as well as monthly-ish injections while cutting the visit count? That's the number to read.

✅ The Edge: A six-month redosing interval, if it holds non-inferior vision outcomes, directly attacks the injection-frequency burden that Eylea and Vabysmo can't fully solve — the clearest differentiator in a mechanism-crowded field.
⚠️ The Risk: Anti-VEGF non-inferiority margins are unforgiving — if DURAVYU gives up even modest visual acuity for the longer interval, payers and retina specialists may not trade efficacy for convenience.

#10. IONS — Ionis Pharmaceuticals Inc.

THE CATALYST
Event: Wainua (eplontersen) — full CARDIO-TTRansform results (primary endpoint already MISSED) presented at ESC
Date: Aug 31, 2026
FDA Status: FTD
BSI: 6.2/10

Read this one carefully: the trial already failed. On July 9, Ionis and partner AstraZeneca reported that the Phase 3 CARDIO-TTRansform study of eplontersen in ATTR cardiomyopathy did not meet its primary endpoint — and the stock has since collapsed, down 31% on the month to an RSI of 10. The "catalyst" here is not a pending readout; it's the presentation of the detailed, already-negative dataset at the ESC Congress in late August. What's live is whether the subgroup analysis is enough to keep a development path open.

📈 The Setup: ATTR cardiomyopathy (a disease where a misfolded transport protein deposits in and stiffens the heart) is now dominated by oral stabilizers — Pfizer's tafamidis (Vyndaqel) and BridgeBio's acoramidis (Attruby) — that most patients receive as standard care. Eplontersen is an antisense drug that silences the source protein rather than stabilizing it. In CARDIO-TTRansform, layered on top of a patient population where most were already on a stabilizer, it failed to show a statistically significant benefit on the composite of cardiovascular death and events through week 140. The one thread the bulls will pull: a prespecified monotherapy subgroup — patients not on a background stabilizer — showed a nominally significant hazard ratio of 0.71, and imaging and biomarker measures leaned favorable. That is a post-hoc-flavored salvage signal, not a win.

✅ The Edge: Eplontersen still delivers large, sustained reductions in the disease-causing protein with a clean safety profile, and the monotherapy subgroup hints at a defensible niche in stabilizer-naïve patients — a narrow but real path if the ESC data hold up to scrutiny.
⚠️ The Risk: The trial missed. Rescuing a program on a subgroup is historically a hard sell — FDA has resisted composite endpoints in ATTR-CM without a clear mortality benefit, and stabilizers already own the market the drug would have to enter through the front door.

WATCHLIST

#11. SION — Sionna Therapeutics Inc. [Cystic Fibrosis]

Price: $45.38 | Cap: $2.0B | Cash: ~$187M | RSI: 51 | Momentum: +7.6%
SION-451 + galicaftor (SION-2222) — Phase 1 topline in healthy volunteers (Aug 2026 (Est.))
BSI: 6.14/10

The Intel: Sionna is chasing Vertex's cystic fibrosis monopoly (Trikafta/Alyftrek) with a differentiated approach that targets the NBD1 region of the CFTR protein, where Vertex's correctors don't act. Worth flagging what this readout actually is: a Phase 1 in healthy volunteers, so it delivers pharmacokinetics and safety, not patient efficacy. With a strong runway and three catalysts in the window, it's a name to track — but this specific data point can't validate the clinical thesis, only clear the path to trials that can.

#12. RARE — Ultragenyx Pharmaceutical Inc. [Gene Therapy / Rare Disease]

Price: $26.89 | Cap: $2.6B | Cash: ~$153M | RSI: 1 | Momentum: -12.6%
DTX401 AAV gene therapy — PDUFA regulatory decision in Glycogen Storage Disease Type Ia (Aug 23, 2026)
BSI: 6.13/10

The Intel: A first-of-its-kind AAV gene therapy for GSDIa (an inherited disorder where the body can't release stored glucose, forcing constant cornstarch dosing to avoid dangerous lows), facing an August PDUFA. There's no drug competitor — the comparator is lifelong dietary management. The scanner's RSI reading of 1 is almost certainly a data artifact rather than a real technical, but the negative momentum and cash-crunch flag are consistent with a beaten-down pre-approval microcap. Binary approval decision on a genuinely novel modality.

#13. CHRS — Coherus Oncology Inc. [Oncology]

Price: $1.46 | Cap: $225M | Cash: ~$91M | RSI: 28 | Momentum: -2.7%
Casdozokitug + toripalimab + bevacizumab — Phase 2 data in liver cancer (HCC) (Aug 2026 (Est.))
BSI: 5.99/10

The Intel: Coherus is testing casdozokitug (an anti-IL-27 antibody) on top of its own PD-1 drug toripalimab (Loqtorzi) plus bevacizumab in first-line hepatocellular carcinoma — going up against the entrenched atezolizumab-plus-bevacizumab (Tecentriq/Avastin) standard. Prior data showed durability and a 17% complete-response rate, which is notable in HCC. But at a $1.46 stock in a crowded checkpoint-combo field, the weak competitive positioning is the concern: it needs to clearly beat, not match, a regimen physicians already trust.

#14. NTHI — NeOnc Technologies Holdings Inc. [Neuro-Oncology]

Price: $3.44 | Cap: $89M | Cash: ~$0.9M | RSI: 31 | Momentum: -24.9%
NEO100 — Phase 1/2a data in recurrent IDH1-mutant astrocytoma (Aug 2026 (Est.))
BSI: 5.98/10

The Intel: The financing situation dominates here — roughly $0.9M in cash against a Phase 2a readout is a near-empty tank, and a raise looks unavoidable regardless of the data. NEO100 (an intranasal formulation of perillyl alcohol) reported radiographic remission in 6 of 25 patients earlier. The problem is the competitive backdrop: Servier's vorasidenib (Voranigo) is now an approved oral drug for IDH-mutant glioma, raising the bar sharply for an early-stage, small-N asset. Speculative, cash-constrained, and facing a real approved competitor.

#15. RYTM — Rhythm Pharmaceuticals Inc. [Rare Endocrine / Obesity]

Price: $106.13 | Cap: $7.3B | Cash: ~$282M | RSI: 35 | Momentum: -3.4%
RM-718 — Phase 1/2 interim data in hypothalamic obesity (Aug 2026 (Est.))
BSI: 5.89/10

The Intel: Rhythm owns the MC4R-pathway franchise in rare genetic obesity via setmelanotide (Imcivree), and RM-718 is a next-generation MC4R agonist aimed at hypothalamic obesity (severe weight gain after damage to the brain's appetite center). The commercial logic is strong — it's an area Rhythm already understands better than anyone. This is an early interim look, though, so weigh it as a pipeline-extension signal rather than a value-defining event; the durability and tolerability profile is what matters, not the top-line weight number alone.

#16. STRO — Sutro Biopharma Inc. [Oncology / ADC]

Price: $24.01 | Cap: $398M | Cash: ~$257M | RSI: 17 | Momentum: -21.3%
STRO-004 — Phase 1 initial data in solid tumors (Aug 2026 (Est.))
BSI: 5.83/10

The Intel: Deeply oversold (RSI 17, down 21% on the month) with a comfortable cash position, Sutro brings its next antibody-drug conjugate, STRO-004, to a first clinical look. The candor here: this is first-cohort dose-escalation data with limited prior evidence behind it, in a solid-tumor ADC field that has grown intensely competitive (Pfizer's Tivdak and a wave of tissue-factor and next-gen ADCs). Read it as a safety-and-early-activity signal, not a differentiating efficacy event — the data strength going in is thin.

#17. CABA — Cabaletta Bio Inc. [Autoimmune / Cell Therapy]

Price: $2.72 | Cap: $444M | Cash: ~$210M | RSI: 34 | Momentum: -10.5%
Resecabtagene autoleucel (rese-cel) — Phase 1/2 interim update in generalized myasthenia gravis (Aug 2026 (Est.))
BSI: 5.79/10

The Intel: Cabaletta is pushing CD19 CAR-T (engineered immune cells that wipe out antibody-producing B cells) into autoimmune disease, with an update in generalized myasthenia gravis (a disorder where antibodies attack the nerve-muscle junction, causing severe weakness). The bull case is a one-time reset versus chronic therapy. But gMG already has effective, far less invasive options — FcRn inhibitors like efgartigimod (Vyvgart) and complement blockers — so a CAR-T with its own conditioning and safety burden faces a steep risk/benefit comparison. Interim data; watch depth and durability of response.

#18. TLX — Telix Pharmaceuticals Limited [Radiopharmaceuticals]

Price: $9.98 | Cap: $3.4B | Cash: ~$750M | RSI: 29 | Momentum: -6.4%
TLX101-Px — PDUFA regulatory decision in recurrent/progressive glioma (Sep 11, 2026)
FDA Status: FTD, ODD
BSI: 5.68/10

The Intel: Important context the headline date hides: this is a resubmission after the FDA issued a Complete Response Letter (a rejection) in April 2025, with a new PDUFA set for September. TLX101 is a targeted radiotherapy for glioma (aggressive brain cancer) delivering radiation to tumor cells via a small-molecule carrier. Telix has a real commercial radiopharma base, but the prior CRL makes the regulatory pathway the dominant risk — a second FDA look with an unresolved earlier concern is a higher bar than a first-time filing.

#19. ACET — Adicet Bio Inc. [Autoimmune / Cell Therapy]

Price: $8.06 | Cap: $75M | Cash: ~$109M | RSI: 44 | Momentum: -3.7%
Prulacabtagene leucel (prula-cel) — Phase 2 interim data in systemic lupus erythematosus (Aug 2026 (Est.))
FDA Status: FTD
BSI: 5.65/10

The Intel: Trading below cash — a $75M market cap against ~$109M in the bank (negative enterprise value), which is the market pricing in real doubt. Adicet's angle is an allogeneic (off-the-shelf, donor-derived) gamma-delta CAR-T for lupus, aiming to avoid the custom-manufacturing bottleneck of autologous CD19 CAR-T rivals like Cabaletta and Kyverna. That's a genuine differentiator if it works — but allogeneic cell therapies face persistence and durability questions autologous approaches don't, and this is an early Phase 2 look. Deep-value optionality with binary science risk.

#20. AVIR — Atea Pharmaceuticals Inc. [Antiviral]

Price: $4.82 | Cap: $386M | Cash: ~$195M | RSI: 48 | Momentum: +7.3%
Bemnifosbuvir + ruzasvir — Phase 3 topline in Hepatitis C (Aug 2026 (Est.))
BSI: 5.55/10

The Intel: Atea's C-BEYOND Phase 3 tests an all-oral, shorter-course hepatitis C combination targeting a 12-week cure (SVR12). The mechanism and catalyst quality are fine — the hard question is commercial, and it's why this sits at the bottom of the list. HCV is a solved, shrinking market dominated by Gilead's Epclusa and AbbVie's Mavyret at low prices; even a clean Phase 3 win runs into the question of who's left to treat and at what margin. Positive data is plausible; a differentiated commercial path is the real hurdle.

About This Scanner

This weekly report identifies biotech catalyst opportunities using quantitative screening combined with fundamental analysis.

What the Score Means: The BSI Score (0-10) reflects overall opportunity quality based on technical setup and fundamental characteristics. Higher scores indicate more favorable setups; lower scores indicate elevated uncertainty. This is NOT a prediction of catalyst outcomes or stock direction.

Data Sources: Financial data from market feeds and regulatory filings. Catalyst dates are estimates based on company guidance and subject to change. Where a company's reported cash was flagged as conflicting with our feed, figures shown reflect the reconciled value from filings.

Important: This report is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. Conduct your own due diligence before making investment decisions.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.

Scanner Version: 3.3 | Generated: 2026-07-28T10:37:43